Altimmune, Inc. (ALT) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Altimmune, Inc. (ALT:NASDAQ), powered by AI.

Current Price
$3.04
P/E Ratio
-3.0
Market Cap
268M
Sector
Healthcare
What is the Altimmune, Inc. stock price forecast?

Altimmune, Inc. is currently trading at $3.04. View real-time AI analysis on Alpha Lenz.

What is Altimmune, Inc. insider trading activity?

View the latest insider trading data for Altimmune, Inc. on Alpha Lenz.

What is Altimmune, Inc.'s P/E ratio?

Altimmune, Inc.'s P/E ratio is -3.0.

Altimmune, Inc.

NASDAQ · ALT
$3.04-0.22(-6.75%)Market closedNASDAQ regular session 09:30–16:00 ET
Ask about Altimmune, Inc.'s future dividend policy...
Alpha Chat Insight

Altimmune, Inc. trades at a P/E of -3.0 (undervalued) with modest ROE of -50.6%.

Ask for details

Company Overview

Altimmune, Inc. is a biopharmaceutical company engaged in the development of immunotherapeutics that address significant unmet medical needs. The company's primary focus is on advancing proprietary therapeutic candidates for the treatment of liver disease, obesity, and infectious diseases. Altimmune's innovative pipeline includes a range of product candidates that leverage unique non-invasive delivery methods, enhancing the therapeutic potential and patient compliance. As a player in the healthcare and life sciences sector, Altimmune, Inc. contributes to the development of cutting-edge treatments that have the potential to improve patient outcomes across various global health challenges. Headquartered in Gaithersburg, Maryland, Altimmune is positioned at the forefront of biopharmaceutical innovation, playing a crucial role in the expanding field of immunotherapy and biotechnological advancements. Its endeavors are significant in addressing critical health issues, potentially reshaping therapeutic approaches in the respective areas.

CEODr. Vipin K. Garg Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees59

Company Statistics

FY 2025

Profile

$267.84MMarket Cap
$41.00KRevenue
0.00Shares Out
59Employees

Margins

N/AGross
-212258.54%EBITDA
-230460.98%Operating
-216521.95%Pre-Tax
-214860.98%Net

Valuation

-3.04P/E
1.19P/B
6532.60EV/Sales
-2.98EV/EBITDA
-3.97P/FCF

Growth (CAGR)

N/ARev 3Yr
-65.33%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-42.03%ROA
-50.57%ROE
-41.57%ROIC

Financial Health

$43.76MCash & Cash Equivalents
$11.28MNet Debt
24.47%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Altimmune, Inc. (ticker: ALT) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 59 employees. Market cap is $268M.

The current price is $3.04 with a P/E ratio of -3.04x and P/B of 1.19x.

ROE is -50.57% and operating margin is -230460.98%. Annual revenue is $41,000.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Altimmune, Inc. (Healthcare) Stock Forecast & Analysis $3.04 | Alpha Lenz